| Literature DB >> 24669771 |
Ram Venkatesh Anantha, Dave Paskar, Kelly Vogt, Silvie Crawford, Neil Parry, Ken Leslie1.
Abstract
INTRODUCTION: Acute care surgical services provide timely comprehensive emergency general surgical care while optimizing the use of limited resources. At our institution, 50% of the daily dedicated operating room (OR) time allocated to the Acute Care Emergency Surgery Service (ACCESS) came from previous elective general surgery OR time. We assessed the impact of this change in resource allocation on wait-times for elective general surgery cancer cases.Entities:
Year: 2014 PMID: 24669771 PMCID: PMC3986936 DOI: 10.1186/1749-7922-9-21
Source DB: PubMed Journal: World J Emerg Surg ISSN: 1749-7922 Impact factor: 5.469
Recommended target wait times (days) for cancer operations based on assigned priority category, as established by the Cancer Care Ontario sub-committee on cancer wait times
| P1 | Patients requiring surgery to remove known or suspected cancers that have immediately life-threatening conditions (e.g., airway obstruction, hemorrhage, neurological compromise) | Immediate | Immediate |
| P2 | Patients diagnosed with very aggressive tumours, such as central nervous system (CNS) cancer | 14 | 14 |
| P3 | All patients with known or suspected invasive cancer that does not meet the criteria of urgency category II or IV | 14 | 28 |
| P4 | Patients diagnosed with indolent tumours | 14 | 84 |
*From the date of the patient’s first visit to the operating surgeon for this specific problem until the decision-to-treat date. The decision-to-treat date is the date on which sufficient pre-treatment testing is complete, the physician can reasonably assume that the patient will be treated, and the patient has agreed to the treatment. By this date, sufficient assessment will have been completed in order to reasonably assume that the procedure will go ahead, and an operating room booking is requested.
Distribution of elective cancer operations performed by general surgeons at Victoria Hospital, before (pre-ACCESS) and after (post-ACCESS) the implementation of ACCESS
| Number of cases, n | 367 | 365 | -2 (-1) | - |
| Number of cases by priority, n (%) | | | | <0.0001 |
| P2 | 21 (6) | 1 (0.3) | -20 (-95) | |
| P3 | 277 (75) | 167 (46) | -110 (-40) | |
| P4 | 69 (19) | 197 (54) | +128 (+185) | |
| Number of cases exceeding wait-time targets, n (%) | | | | <0.0001 |
| P2 | 13 (62) | 0 (0) | -13 (-100) | |
| P3 | 92 (33) | 41 (25) | -51 (-55) | |
| P4 | 2 (3) | 2 (1) | 0 (0) | |
| Median wait-times by priority, days (range) | | | | 0.94 |
| P2 | 15 (2–29) | 9 (N/A) | -6 (-40) | |
| P3 | 21 (0–90) | 15 (0–90) | -6 (-29) | |
| P4 | 33 (6–92) | 22 (0–90) | -11 (-33) | |
| Type of cancer, n (%) | | | | 0.027 |
| Breast | 104 (28) | 79 (22) | -25 (-24) | |
| Colorectal | 119 (32) | 151 (41) | +32 (+27) | |
| Hepatopancreatobiliary | 8 (2) | 18 (5) | +10 (+125) | |
| Gastric | 10 (3) | 5 (1) | -5 (-50) | |
| Endocrine | 100 (27) | 94 (26) | -6 (-6) | |
| Lymph | 1 (0) | 0 (0) | -1 (-100) | |
| Soft-tissue sarcoma | 6 (2) | 8 (2) | +2 (+33) | |
| Skin carcinoma1 | 4 (1) | 2 (1) | -2 (-50) | |
| Skin melanoma | 15 (4) | 7 (2) | -8 (-53) |
1Includes basal and squamous cell carcinoma.
Distribution of elective cancer operations performed by subspecialty surgical oncologists (non-general surgeons) at Victoria Hospital, before and after the implementation of ACCESS (pre- and post-ACCESS, respectively)
| Number of cases, n | 1685 | 1624 | -61 (-4) | - |
| Number of cases by priority level, n (%) | | | | <0.0001 |
| P2 | 187 (11) | 95 (6) | -92 (-49) | |
| P3 | 1027 (61) | 768 (47) | -259 (-25) | |
| P4 | 471 (28) | 761 (47) | +290 (+62) | |
| No. of cases exceeding wait-time targets by priority, n (%) | | | | 0.39 |
| P2 | 120 (64) | 61 (64) | -59 (-49) | |
| P3 | 485 (47) | 297 (39) | -188 (-39) | |
| P4 | 122 (26) | 118 (16) | -4 (-3) | |
| Median wait-times by priority, days (range) | | | | 0.52 |
| P2 | 19 (1–215) | 17 (1–55) | -2 (-10) | |
| P3 | 27 (0–274) | 23 (0–108) | -4 (-14) | |
| P4 | 66 (0–246) | 41 (0–207) | -25 (-37) | |
| Type of cancer, n (%) | | | | < 0.0001 |
| Gastric | 21 (1) | 10 (0.6) | -11 (-52) | |
| Endocrine | 238 (14) | 172 (11) | -66 (-28) | |
| Genitourinary (excluding prostate) | 228 (14) | 230 (14) | +2 (+1) | |
| Gynecological | 350 (21) | 284 (17) | -66 (-19) | |
| Head and neck (excluding thyroid) | 154 (9) | 276 (17) | +122 (+79) | |
| Lung | 168 (10) | 194 (12) | +26 (+15) | |
| Lymph | 2 (0.1) | 3 (0.2) | +1 (+50) | |
| Peripheral nervous system | 1 (0.1) | 3 (0.2) | +2 (+200) | |
| Prostate | 132 (8) | 105 (6) | -27 (-20) | |
| Skin carcinoma1 | 8 (0.5) | 7 (0.4) | -1 (-13) | |
| Skin melanoma | 49 (3) | 30 (2) | -19 (-39) |
1Includes basal and squamous cell carcinoma.